Gastrointestinal Stromal Tumor: History, Molecular Subtypes, and Risk Stratification
Journal of Gastric Cancer · 2026 · 26 (2) · 202
DOI: 10.5230/jgc.2026.26.e7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Gastric Cancer, 2026. Verfasst von In Hye Song und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Gastrointestinal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The gastrointestinal stromal tumor (GIST) is one of the most common mesenchymal tumors of the gastrointestinal tract. Between the 1990s and early 2000s, GIST was identified as a tumor characterized by KIT or PDGFRA mutations, resulting in imatinib being established as an effective targeted therapy. However, with advances in molecular diagnostics, approximately 10%-15% of GISTs have been reported to harbor alternative mutations, such as those in the succinate dehydrogenase subunit genes and BRAF, leading to the development of additional targeted therapies. GISTs exhibit a wide spectrum of clinical behaviors, ranging from indolent to highly aggressive, prompting the development of diverse risk classification systems. However, multiple systems remain in use, leading to inconsistent pathologic reports. Moreover, the mitotic counting method-a key factor in risk stratification-has become a major source of confusion among pathologists owing to the adoption of digital pathology and discrepancies between updated international guidelines and outdated reimbursement requirements. These inconsistencies have hindered pathologic reporting and communication between pathologists and clinicians. This review comprehensively overviews the historical background, molecular subtypes, and risk classification systems of GIST, focusing on evolving issues in mitotic rate evaluation and the application of risk classification systems in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. miniryu@amc.seoul.kr.
- Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. youngspark@amc.seoul.kr.
ORCID-Profile: In Hye Song, Soomin Ahn, Hyung-Don Kim, Jeong-Hyeon Jo, Jinho Shin, Min-Hee Ryu, Young Soo Park
Zitieren
APA
Song, I. H., Ahn, S., Kim, H. D., Jo, J. H., Shin, J., Ryu, M. H., & Park, Y. S. (2026). Gastrointestinal Stromal Tumor: History, Molecular Subtypes, and Risk Stratification. Journal of Gastric Cancer, 26(2), 202. https://doi.org/10.5230/jgc.2026.26.e7
Vancouver
Song IH, Ahn S, Kim HD, Jo JH, Shin J, Ryu MH, et al. Gastrointestinal Stromal Tumor: History, Molecular Subtypes, and Risk Stratification. Journal of Gastric Cancer. 2026;26(2):202. doi:10.5230/jgc.2026.26.e7
BibTeX
@article{Song2026,
author = {Song, In Hye and Ahn, Soomin and Kim, Hyung-Don and Jo, Jeong-Hyeon and Shin, Jinho and Ryu, Min-Hee and Park, Young Soo},
title = {Gastrointestinal Stromal Tumor: History, Molecular Subtypes, and Risk Stratification},
journal = {Journal of Gastric Cancer},
year = {2026},
volume = {26},
number = {2},
pages = {202},
doi = {10.5230/jgc.2026.26.e7}
}
EUVIMED